Ostatní
Návod 
CRISPR Therapeutics AG
CRSP
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
4.9B
Obrat
0B
Zisk
-1B
Aktiva
2B
Dluh
0B
ROE
0%
ROA
0%
PE
-7
PS
1588
Cena 1R
30-78
⌀ Cena
52.42
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
12-02-2026
Poslední dividenda
Profil
CRISPR Therapeutics AG, společnost zabývající se editací genů, se zaměřuje na vývoj genově založených léků pro závažná onemocnění s využitím své proprietární platformy Clustered Pravidelně proložené krátké palindromické opakování (CRISPR)/CRISPR-ASSOCIATED protein 9 (Cas9). CRISPR/Cas9 je technologie pro úpravu genů, která umožňuje přesné cílené změny genomové DNA. Společnost má portfolio terapeutických programů v celé řadě oblastí onemocnění, včetně hemoglobinopatií, onkologie, regenerativní medicíny a vzácných onemocnění. Hlavní kandidátskou léčbou je CTX001, genově editovaná terapie CRISPR ex vivo pro pacienty trpící beta-talasemií závislou na transfuzi nebo těžkou srpkovitou anémií, při níž jsou pacientovy hematopoetické kmenové buňky konstruovány tak, aby produkovaly vysoké hladiny fetálního hemoglobinu v červených krvinkách. Vyvíjí také CTX110, dárcem odvozenou genově upravenou allogenní CAR-T investigativní terapii zaměřenou na shluk diferenciace 19 pozitivních malignit; CTX120, dárcem odvozenou genově upravenou allogenní CAR-T investigativní terapii zaměřenou na B-buněčný antigen pro léčbu relabujícího nebo refrakterního mnohočetného myelomu; a CTX130, dárcem odvozenou genově upravenou allogenní CAR-T investigativní terapii zaměřenou na Cluster of Differentiation 70 pro léčbu různých solidních tumorů a hematologických malignit. Kromě toho společnost vyvíjí VCTX210, genově editovaný, imunitně vyhýbající se produkt z kmenových buněk, který je kandidátem na léčbu diabetu typu 1, a sleduje různé in vivo programy genových editací, které se zaměřují na onemocnění jater, plic, svalů a centrální nervové soustavy. Má strategická partnerství s Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc. a Capsida Biotherapeutics. CRISPR Therapeutics AG byla založena v roce 2013 a sídlí ve švýcarském Zugu.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
393
Založení
2016-10-19
Podobné společnosti
$ 42.05
+ $ 0.40
$ 40.77
+ $ 1.54
$ 199.73
+ $ 1.80
$ 70.79
- $ 1.00
$ 30.13
- $ 2.12
$ 87.47
+ $ 0.92
$ 61.81
+ $ 1.65
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 2.6 | 3.5 | 35.0 | 371.2 | 0.4 | 913.1 | 0.5 | 289.6 | 3.1 | 41.0 | 5.2 | 0.2 | 0.0 | |
| Cost of Revenues | 226.7 | 233.0 | 110.3 | 130.3 | 110.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | -224.1 | -229.4 | -75.3 | 241.0 | -109.8 | 913.1 | 0.5 | 289.6 | 3.1 | 41.0 | 5.2 | 0.2 | 0.0 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 0.9 | 0.9 | 0.0 | 0.9 | 35.0 | 0.0 | 0.5 | 0.5 | 200.0 | 0.0 | |
| Cost of Revenues | 59.4 | 64.7 | 45.2 | 57.5 | 0.0 | 11.2 | 57.0 | 51.8 | 20.0 | 23.4 | |
| Gross Profit | -58.5 | -63.8 | -45.2 | -56.6 | 35.0 | -11.2 | -56.5 | -51.3 | 180.0 | -23.4 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 387.3 | 461.6 | 438.6 | 266.9 | 179.4 | 113.8 | 69.8 | 42.2 | 12.6 | 1.5 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 76.2 | 102.5 | 102.8 | 88.2 | 63.5 | 48.3 | 35.8 | 31.1 | 13.4 | 5.1 | |
| Depreciation & Amortization | 19.5 | 19.5 | 19.3 | 19.8 | 24.2 | 18.0 | 9.2 | 4.7 | 3.5 | 3.0 | 0.9 | 0.1 | 0.0 | |
| Total Operating Expenses | 440.5 | 338.9 | 391.3 | 463.5 | 563.3 | 539.6 | 355.0 | 242.9 | 162.1 | 105.6 | 73.3 | 26.0 | 6.6 | |
| Operating Income | -664.6 | -568.3 | -466.6 | -222.5 | -673.2 | 373.5 | -354.4 | 46.7 | -158.9 | -64.6 | -68.1 | -25.7 | -6.6 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 95.1 | 90.7 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.5 | 18.3 | ||
| Depreciation & Amortization | 5.7 | 4.4 | 4.6 | 4.7 | 4.8 | 4.7 | 4.8 | 4.8 | 4.9 | 4.9 | ||
| Total Operating Expenses | 96.3 | 68.3 | 184.2 | 91.8 | 99.6 | 99.0 | 94.8 | 89.3 | 110.4 | 109.0 | ||
| Operating Income | -154.8 | -132.1 | -229.3 | -148.4 | -64.6 | -110.1 | -151.3 | -140.6 | 69.6 | -132.4 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | -46.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.1 | 0.1 | 0.0 | |
| Other Expense | 86.6 | -9.6 | 103.9 | 71.8 | 22.7 | 6.0 | 6.4 | 20.6 | -5.5 | -2.0 | 53.5 | 0.0 | -0.2 | |
| IBT | -578.0 | -578.0 | -362.7 | -150.7 | -650.5 | 379.5 | -348.1 | 67.3 | -164.4 | -66.6 | -22.7 | -25.8 | -6.9 | |
| Income Tax Expense | 3.6 | 3.6 | 3.6 | 2.9 | -0.3 | 1.9 | 0.8 | 0.4 | 0.6 | 1.7 | 0.5 | 0.0 | -0.1 | |
| Net Income | -581.6 | -581.6 | -366.3 | -153.6 | -650.2 | 377.7 | -348.9 | 66.9 | -165.0 | -68.4 | -23.2 | -25.8 | -6.8 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.7 | ||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Other Expense | 24.8 | 26.2 | 22.1 | 13.5 | 28.0 | 25.1 | 26.1 | 24.7 | 20.0 | 20.7 | ||
| IBT | -130.0 | -105.8 | -207.3 | -134.9 | -36.6 | -85.1 | -125.1 | -115.9 | 89.6 | -111.7 | ||
| Income Tax Expense | 0.6 | 0.6 | 1.3 | 1.1 | 0.7 | 0.9 | 1.3 | 0.7 | 0.2 | -0.4 | ||
| Net Income | -130.6 | -106.4 | -208.5 | -136.0 | -37.3 | -85.9 | -126.4 | -116.6 | 89.3 | -112.2 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | $-1.89 | $-0.88 | $-0.23 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-1.89 | $-0.88 | $-0.23 | |
| Shares Outstanding | 89.9 | 89.9 | 84.4 | 79.2 | 77.7 | 75.9 | 65.9 | 54.4 | 48.0 | 40.1 | 12.3 | 29.3 | 29.3 | |
| Diluted Shares Outstanding | 89.9 | 89.9 | 84.4 | 79.2 | 77.7 | 80.4 | 65.9 | 56.9 | 48.0 | 40.1 | 12.3 | 29.3 | 29.3 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.12 | $-1.41 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.10 | $-1.41 | ||
| Shares Outstanding | 89.9 | 91.3 | 87.1 | 85.9 | 85.5 | 85.2 | 84.9 | 81.8 | 79.7 | 79.4 | ||
| Diluted Shares Outstanding | 89.9 | 91.3 | 87.1 | 85.9 | 85.5 | 85.2 | 84.9 | 81.8 | 81.3 | 79.4 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 484.5 | 298.3 | 389.5 | 211.9 | 923.0 | 1,168.6 | 943.8 | 456.6 | 239.8 | 315.5 | 156.0 | 0.9 | |
| Short Term Investments | 1,517.1 | 1,605.6 | 1,304.2 | 1,603.4 | 1,456.1 | 521.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 2,001.6 | 1,903.8 | 1,693.7 | 1,815.3 | 2,379.1 | 1,690.3 | 943.8 | 456.6 | 239.8 | 315.5 | 156.0 | 0.9 | |
| Accounts Receivable | 0.0 | 25.0 | 200.0 | 0.0 | 0.3 | 0.1 | 0.1 | 0.1 | 2.6 | 3.2 | 0.3 | 0.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 8.8 | 8.3 | 14.4 | 37.7 | 38.1 | 26.1 | 43.7 | 9.7 | 6.0 | 1.5 | 0.5 | 0.0 | |
| Total Current Assets | 2,010.4 | 1,937.1 | 1,908.1 | 1,853.0 | 2,417.5 | 1,716.6 | 987.5 | 466.4 | 248.4 | 320.2 | 156.8 | 1.0 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 286.5 | 197.1 | 235.2 | 298.3 | 225.7 | 484.5 | 707.4 | 389.5 | 527.8 | 444.8 | |
| Short Term Investments | 1,629.2 | 1,527.6 | 1,620.1 | 1,605.6 | 1,710.0 | 1,517.1 | 1,400.7 | 1,304.2 | 1,212.1 | 1,323.3 | |
| Total Cash & ST Investments | 1,915.7 | 1,724.8 | 1,855.3 | 1,903.8 | 1,935.6 | 2,001.6 | 2,108.1 | 1,693.7 | 1,739.8 | 1,768.1 | |
| Accounts Receivable | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 | 0.0 | 0.0 | 200.0 | 0.0 | 70.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 13.4 | 8.9 | 12.3 | 8.3 | 8.2 | 8.8 | 11.5 | 14.4 | 20.8 | 21.5 | |
| Total Current Assets | 1,929.1 | 1,733.7 | 1,867.6 | 1,937.1 | 1,943.9 | 2,010.4 | 2,119.6 | 1,908.1 | 1,760.6 | 1,859.6 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 291.6 | 277.6 | 305.9 | 320.6 | 312.0 | 93.0 | 72.8 | 18.5 | 18.9 | 21.0 | 1.3 | 0.0 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | |
| Long-Term Investments | 22.7 | 0.0 | 2.0 | 53.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 15.1 | 27.3 | 13.6 | 16.3 | 22.2 | 18.1 | 6.1 | 3.8 | 3.8 | 3.3 | 0.8 | 0.1 | |
| Total Long-Term Assets | 329.4 | 304.9 | 321.5 | 390.0 | 334.4 | 111.3 | 79.2 | 22.6 | 23.0 | 24.8 | 2.6 | 0.6 | |
| Total Assets | 2,339.9 | 2,242.0 | 2,229.6 | 2,243.1 | 2,751.9 | 1,828.0 | 1,066.8 | 489.0 | 271.3 | 345.0 | 159.4 | 1.5 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 255.5 | 262.6 | 269.7 | 277.6 | 284.8 | 291.6 | 298.5 | 305.9 | 312.3 | 318.5 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 28.4 | 30.6 | 0.0 | 0.0 | 0.0 | 11.2 | 11.5 | 2.0 | 11.8 | 4.9 | |
| Other Long-Term Assets | 32.3 | 2.9 | 28.8 | 27.3 | 27.4 | 26.7 | 20.9 | 13.6 | 13.9 | 14.0 | |
| Total Long-Term Assets | 316.2 | 296.0 | 298.5 | 304.9 | 312.2 | 329.4 | 319.4 | 321.5 | 326.2 | 337.4 | |
| Total Assets | 2,245.3 | 2,029.7 | 2,166.1 | 2,242.0 | 2,256.1 | 2,339.9 | 2,439.0 | 2,229.6 | 2,086.8 | 2,197.0 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 9.5 | 14.7 | 38.1 | 27.4 | 14.8 | 9.1 | 5.9 | 5.1 | 1.6 | 4.6 | 1.6 | 0.2 | |
| Short-Term Debt | 16.5 | 17.3 | 31.3 | 15.8 | 12.2 | 11.4 | 8.5 | -35.3 | -44.2 | -60.3 | 0.0 | 0.0 | |
| Other Current Liabilities | 97.2 | 51.5 | 34.9 | 65.5 | 91.9 | 71.5 | 41.7 | 0.2 | 0.1 | 0.1 | 8.6 | 1.9 | |
| Current Liabilities | 127.8 | 87.8 | 108.8 | 121.1 | 119.9 | 94.3 | 57.1 | 27.7 | 14.5 | 22.0 | 10.2 | 2.1 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 11.8 | 9.8 | 13.1 | 14.7 | 15.6 | 9.5 | 16.5 | 38.1 | 26.2 | 27.6 | |
| Short-Term Debt | 18.3 | 18.0 | 17.5 | 17.3 | 16.9 | 16.5 | 16.0 | 31.3 | 30.0 | 29.7 | |
| Other Current Liabilities | 84.2 | 73.7 | 84.6 | 51.5 | 52.0 | 96.7 | 81.3 | 34.9 | 86.9 | 75.0 | |
| Current Liabilities | 119.0 | 104.4 | 119.4 | 87.8 | 89.8 | 127.8 | 119.0 | 108.8 | 111.2 | 132.8 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 214.9 | 206.4 | 223.0 | 228.2 | 212.9 | 50.1 | 44.1 | 0.0 | 0.0 | 0.0 | 38.3 | 0.0 | |
| Capital Leases | 214.9 | 223.7 | 238.6 | 244.0 | 225.0 | 61.4 | 52.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 64.5 | 0.0 | |
| Total Liabilities | 358.9 | 310.0 | 346.8 | 367.6 | 352.4 | 163.7 | 127.3 | 96.8 | 83.5 | 112.1 | 188.5 | 8.5 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 192.8 | 197.4 | 201.9 | 206.4 | 210.7 | 214.9 | 218.9 | 223.0 | 226.6 | 230.3 | |
| Capital Leases | 211.0 | 215.5 | 219.4 | 223.7 | 227.5 | 231.3 | 218.9 | 238.6 | 241.6 | 245.2 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 329.3 | 318.6 | 336.9 | 310.0 | 316.5 | 358.9 | 355.1 | 346.8 | 359.0 | 381.0 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 2.7 | 2.7 | 2.5 | 2.4 | 2.4 | 2.3 | 1.8 | 1.6 | 1.2 | 1.2 | 0.2 | 0.1 | |
| Retained Earnings | -1,242.7 | -1,366.0 | -999.7 | -846.1 | -195.9 | -573.6 | -224.7 | -291.6 | -125.4 | -57.1 | -33.9 | -8.4 | |
| Comprehensive Income | -2.9 | 1.8 | 1.9 | -15.6 | -5.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Common Equity | 1,980.9 | 1,932.1 | 1,882.8 | 1,875.5 | 2,399.5 | 1,664.2 | 939.4 | 392.2 | 187.8 | 232.8 | -29.1 | -7.1 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 3.0 | 2.8 | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 | 2.5 | 2.5 | 2.5 | |
| Retained Earnings | -1,816.9 | -1,710.5 | -1,501.9 | -1,366.0 | -1,328.6 | -1,242.7 | -1,116.3 | -999.7 | -1,089.0 | -976.9 | |
| Comprehensive Income | 5.0 | 4.0 | 4.1 | 1.8 | 10.6 | -2.9 | -1.6 | 1.9 | -6.8 | -8.9 | |
| Total Common Equity | 1,916.0 | 1,711.1 | 1,829.2 | 1,932.1 | 1,939.7 | 1,980.9 | 2,083.9 | 1,882.8 | 1,727.8 | 1,816.0 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 231.3 | 223.7 | 238.6 | 244.0 | 225.0 | 61.4 | 52.5 | 0.0 | 0.0 | 0.0 | 38.3 | 0.0 | |
| Book Value | 1,980.9 | 1,932.1 | 1,882.8 | 1,875.5 | 2,399.5 | 1,664.2 | 939.4 | 392.2 | 187.8 | 232.8 | -29.1 | -7.0 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 1,916.0 | 1,711.1 | 1,829.2 | 1,932.1 | 1,939.7 | 1,980.9 | 2,083.9 | 1,882.8 | 1,727.8 | 1,816.0 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -265.8 | -581.6 | -366.3 | -153.6 | -650.2 | 377.7 | -348.9 | 66.9 | -165.0 | -68.4 | -23.2 | -25.8 | -6.8 | |
| Depreciation & Amortization | 19.5 | 19.5 | 19.3 | 19.8 | 24.2 | 18.0 | 9.2 | 4.7 | 3.5 | 3.0 | 0.9 | 0.1 | 0.0 | |
| Stock-Based Compensation | 81.5 | 72.5 | 86.6 | 81.0 | 97.9 | 102.4 | 66.0 | 44.1 | 35.0 | 18.9 | 10.8 | 3.7 | 0.7 | |
| Change Working Capital | 69.6 | 71.9 | 156.3 | -193.6 | 19.8 | 26.9 | 33.4 | -48.4 | 10.6 | -25.4 | 1.8 | 81.4 | 1.5 | |
| Change In Accounts Receivable | 70.0 | 25.0 | 175.0 | -200.0 | 0.3 | -0.2 | 0.0 | 0.0 | 2.5 | 0.5 | -2.8 | -0.3 | 0.0 | |
| Change In Accounts Payable | -15.2 | 44.9 | 0.0 | -20.2 | 5.2 | 37.5 | 25.7 | 5.0 | -323.3 | 546.6 | 3.9 | 0.0 | 0.0 | |
| Change In Inventories | 33.9 | 0.0 | 0.0 | 23.3 | 0.0 | -37.5 | -25.7 | -5.0 | 332.3 | -551.3 | -1.1 | 0.0 | 0.0 | |
| Other Non-cash Items | -182.8 | 72.7 | -38.6 | -14.0 | 12.5 | 14.1 | 1.9 | -10.5 | 15.4 | 1.8 | 8.1 | 0.1 | -0.3 | |
| Cash from Operations | -121.8 | 0.0 | 0.0 | -260.4 | -495.7 | 539.0 | -238.4 | 56.7 | -96.2 | -70.1 | -55.3 | 59.4 | -4.8 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -130.6 | -106.4 | -208.5 | -136.0 | -37.3 | -85.9 | -126.4 | -116.6 | 89.3 | -112.2 | |
| Depreciation & Amortization | 5.7 | 4.4 | 4.6 | 4.7 | 4.8 | 4.7 | 4.8 | 4.8 | 4.9 | 4.9 | |
| Stock-Based Compensation | 18.1 | 16.6 | 17.6 | 20.2 | 21.9 | 21.5 | 23.7 | 19.4 | 18.4 | 20.0 | |
| Change Working Capital | 22.6 | 10.9 | -16.5 | 54.8 | -24.4 | -40.4 | 10.5 | 210.5 | -204.0 | 52.6 | |
| Change In Accounts Receivable | 0.0 | 0.0 | 0.0 | 25.0 | -25.0 | 0.0 | 0.0 | 200.0 | -200.0 | 70.0 | |
| Change In Accounts Payable | 0.0 | 12.2 | -14.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.2 | -24.7 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.2 | 24.7 | |
| Other Non-cash Items | -8.3 | -10.1 | 88.9 | 2.3 | -15.2 | -6.9 | -8.2 | -8.4 | -4.8 | -5.2 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -96.1 | -39.9 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -4.3 | -0.9 | -1.9 | -9.5 | -37.2 | -81.7 | -18.4 | -6.7 | -2.8 | -7.8 | -3.0 | -1.2 | 0.0 | |
| Acquisitions | 80.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | |
| Investments | -1,423.9 | -1,008.2 | -1,486.4 | -1,065.9 | -1,417.8 | -1,509.3 | -594.0 | 0.0 | 0.0 | -0.5 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 1,244.4 | 1,011.3 | 1,207.8 | 1,452.5 | 1,196.3 | 555.6 | 71.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | -215.4 | 0.0 | 0.0 | -2.5 | 0.0 | 0.0 | 0.0 | 8.0 | 0.0 | 0.0 | 35.0 | 0.0 | 0.0 | |
| Cash from Investing | -184.8 | 0.0 | 0.0 | 374.6 | -258.7 | -1,035.4 | -541.2 | 1.3 | -2.8 | -8.3 | 31.9 | -1.2 | 0.0 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.5 | -0.1 | -0.1 | -0.2 | -0.3 | -0.2 | -0.7 | -0.7 | -0.7 | -2.1 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 80.7 | 0.0 | |
| Investments | -263.0 | -334.1 | -215.1 | -205.7 | -266.9 | -409.1 | -476.0 | -334.4 | -368.1 | -245.4 | |
| Sales of Investment | 300.7 | 214.9 | 310.2 | 186.2 | 373.0 | 247.7 | 349.8 | 237.3 | 287.4 | 369.9 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -80.7 | -1.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -81.5 | 121.3 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | -13.9 | 223.7 | -14.9 | -5.4 | 19.0 | 163.6 | 8.9 | 52.5 | 0.0 | 0.0 | -38.3 | 38.3 | 0.0 | |
| Issuance of Common Stock | 339.7 | 0.0 | 0.0 | 32.7 | 1.0 | 213.3 | 982.3 | 415.0 | 307.1 | 0.0 | 89.1 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 313.7 | 0.0 | 0.0 | 29.9 | 37.6 | 37.7 | 33.9 | 16.0 | 8.9 | 2.6 | 94.2 | 96.7 | 5.1 | |
| Cash from Financing | 346.0 | 0.0 | 0.0 | 62.7 | 38.6 | 250.9 | 1,016.2 | 431.0 | 315.9 | 2.6 | 183.2 | 96.7 | 5.1 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 211.0 | -4.4 | -3.9 | -4.3 | -3.9 | -3.8 | -3.6 | -3.7 | -3.0 | -3.6 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 32.7 | 1.6 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 1.6 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 38.9 | 1.6 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 39.5 | 49.3 | -91.3 | 177.0 | -715.9 | -245.5 | 236.7 | 489.0 | 216.9 | -75.8 | 159.6 | 155.0 | 0.6 | |
| Closing Cash Balance | 484.5 | 359.1 | 309.8 | 401.1 | 224.1 | 939.9 | 1,185.5 | 948.8 | 459.8 | 239.8 | 315.5 | 156.0 | 0.9 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 61.1 | 92.9 | -41.6 | -63.1 | 72.6 | -258.8 | -223.0 | 317.9 | -138.5 | 83.0 | |
| Closing Cash Balance | 359.1 | 298.0 | 197.1 | 246.7 | 309.8 | 237.2 | 496.0 | 718.9 | 401.1 | 539.6 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -126.0 | -345.9 | -144.7 | -272.3 | -532.9 | 457.3 | -256.7 | 50.0 | -99.0 | -77.9 | -58.3 | 58.3 | -4.8 | |
| Real Free Cash Flow | -207.5 | -418.4 | -231.2 | -353.4 | -630.9 | 354.9 | -322.7 | 5.9 | -134.0 | -96.8 | -69.2 | 54.6 | -5.5 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -93.1 | -84.7 | -114.0 | -54.2 | -50.3 | -107.1 | -96.3 | 109.0 | -96.8 | -42.0 | |
| Real Free Cash Flow | -111.1 | -101.3 | -131.6 | -74.4 | -72.2 | -128.7 | -120.0 | 89.6 | -115.2 | -61.9 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -7.1 | -8.5 | -1.4 |
| P/S | 1588.3 | 1353.3 | 9.4 |
| P/B | 2.2 | 3.6 | 5.2 |
| P/FCF | -9.9 | -29.8 | -1.5 |
| Market cap | $4.9 | $4.4 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 5.9 % | 0 % |
| Debt to Income | -36.3 % | -22.2 % | 0 % |
| Debt to Free cash flow | -50.4 % | -98.1 % | 0 % |
| Interest expense percentage | 0 % | -1.1 % | 44.7 % |
| Current ratio | 16.2 | 15.5 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -30.4 % | -12.4 % | 0 % |
| ROA | -25.9 % | -13 % | 0 % |
| CapEx to Revenue | 34.9 % | 441.7 % | 0 % |
| RaD to Revenue | 0 % | 5997.2 % | 0 % |
| ROEM | 6,661.6 | 353150.9 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | -8560 % | -788.2 % | 68.7 % |
| Operating margin | -25384.7 % | -9038.8 % | 35.5 % |
| Net margin | -22215.4 % | -8725.8 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 89.9 mil | 63.8 mil |
| Employee count | 0.4 tis | 0.3 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
